Benjamin Luke Kendall

Benjamin Luke Kendall

Auto-generated profile, based on publicly available information

Benjamin Luke Kendall

Mayo Clinic 1 Department of Molecular Medicine Rochester, Minnesota

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 December 2021 in The CRISPR Journal
Verified
Journal Article
Open access
ASAnkit Sabharwal
Ankit Sabharwal
BKBibekananda Kar
Bibekananda Kar
SRSantiago Restrepo-Castillo
Santiago Restrepo-Castillo
Shannon Rose HolmbergShannon Rose Holmberg
Shannon Rose Holmberg
NMNeal D. Mathew
Neal D. Mathew
SEStephen C. Ekker
Stephen C. Ekker
Functional analyses of mitochondria have been hampered by few effective approaches to manipulate mitochondrial DNA (mtDNA) and a lack of existing animal models. Recently a TALE-derived base editor was shown to induce C-to-T (or G-to-A) sequence changes in mtDNA. We report here the FusX TALE Base Editor (FusXTBE) to facilitate broad-based access to TALE mitochondrial base editing technology. TALE Writer is a de novo in silico design tool to map potential mtDNA base editing sites. FusXTBE was demonstrated to function with comparable activity to the initial base editor in human cells in vitro . Zebrafish embryos were used as a pioneering in vivo test system, with FusXTBE inducing 90+% editing efficiency in mtDNA loci as an example of near-complete induction of mtDNA heteroplasmy in vivo . Gene editing specificity as precise as a single nucleotide was observed for a protein-coding gene. Nondestructive genotyping enables single-animal mtDNA analyses for downstream biological functional genomic applications. FusXTBE is a new gene editing toolkit for exploring important questions in mitochondrial biology and genetics.

5 October 2020 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
BKBenjamin L. Kendall
Benjamin L. Kendall
JGJeffrey Grabowski
Jeffrey Grabowski
RRRebecca Rosenke
Rebecca Rosenke
MPMikayla Pulliam
Mikayla Pulliam
DLDaniel R. Long
Daniel R. Long
MBMarshall Bloom
Marshall Bloom
Infected Ixodes scapularis (black-legged tick) transmit a host of serious pathogens via their bites, including Borrelia burgdorferi, Babesia microti, and tick-borne flaviviruses (TBFVs), such as Powassan virus (POWV). Although the role of female I. scapularis ticks in disease transmission is well characterized, the role of male ticks is poorly understood. Because the pathogens are delivered in tick saliva, we studied the capacity of male salivary glands (SGs) to support virus replication. Ex vivo cultures of SGs from unfed male I. scapularis were viable for more than a week and maintained the characteristic tissue architecture of lobular ducts and acini. When SG cultures were infected with the TBFVs Langat virus (LGTV) or POWV lineage II (deer tick virus), the production of infectious virus was demonstrated. Using a green fluorescent protein-tagged LGTV and confocal microscopy, we demonstrated LGTV infection within SG acinus types II and III. The presence of LGTV in the acini and lobular ducts of the cultures was also shown via immunohistochemistry. Furthermore, the identification by in situ hybridization of both positive and negative strand LGTV RNA confirmed that the virus was indeed replicating. Finally, transmission electron microscopy of infected SGs revealed virus particles packaged in vesicles or vacuoles adjacent to acinar lumina. These studies support the concept that SGs of male I. scapularis ticks support replication of TBFVs and may play a role in virus transmission, and further refine a useful model system for developing countermeasures against this important group of pathogens. Powassan disease has greatly increased in frequency since its discovery in Powassan, Ontario in 1958. Powassan virus (lineage I; POWV) and Powassan virus lineage II (deer tick virus; DTV) are endemic to North America and there were 133 reported cases between 2009 and 2018, the majority since 2016. Nymphal and adult Ixodes scapularis ticks are thought to be the primary vectors of POWV/DTV to humans. However, little is known regarding DTV infection of male Ixodes ticks or their potential as vectors. In this study we characterized LGTV, a model tick-borne flavivirus, and DTV infection and propagation in male I. scapularis salivary gland cultures using an ex vivo organ culture system. This work provides insight into potential flavivirus transmission by the male I. scapularis tick.

20 May 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
ASAnkit Sabharwal
Ankit Sabharwal
BKBibekananda Kar
Bibekananda Kar
SRSantiago Restrepo-Castillo
Santiago Restrepo-Castillo
Shannon Rose HolmbergShannon Rose Holmberg
Shannon Rose Holmberg
BKBenjamin Luke Kendall
Benjamin Luke Kendall
SEStephen C. Ekker
Stephen C. Ekker
Functional analyses of mitochondria have been hampered by few effective approaches to manipulate mtDNA and a lack of existing animal models. Recently a TALE-derived base editor was shown to induce C-to-T (or G-to-A) sequence changes in mtDNA. We report here the FusX TALE Base Editor (FusXTBE) to facilitate broad-based access to TALE mitochondrial base editing technology. TALE Writer is a de novo in silico design tool to map potential mtDNA base editing sites. FusXTBE was demonstrated to function with comparable activity to the initial base editor in human cells in vitro . Zebrafish embryos were used as a pioneering in vivo test system, with FusXTBE inducing 90+% editing efficiency in mtDNA loci, the first example of majority mtDNA heteroplasmy induction in any system. Gene editing specificity as precise as a single nucleotide was observed in vivo for a protein-coding gene. Non-destructive genotyping enables single animal mtDNA analyses for downstream biological functional genomics applications. FusXTBE is a new gene editing toolkit for exploring important questions in mitochondrial biology and genetics.

5 June 2026 in Science Advances
Verified
Journal Article
Open access
OLOlivia Liseth
Olivia Liseth
EAElizabeth Appleton
Elizabeth Appleton
BKBenjamin Kendall
Benjamin Kendall
JTJill Thompson
Jill Thompson
TSThanich Sangsuwannukul
Thanich Sangsuwannukul
RVRichard D. Vile
Richard D. Vile
Chimeric antigen receptor (CAR) T cell therapy faces many challenges against solid tumors including T cell exhaustion and poor CAR durability. Here, we show that engaging the CAR T cell endogenous T cell receptor (TCR) using an oncolytic virus enhances CAR T cell functionality, durability, and therapy. Upon combination therapy of solid tumors with CAR T cells and vesicular stomatitis virus (VSV), a subpopulation of antiviral, TCR-primed CAR T cells was generated with enhanced effector functions, altered activation states, and differential gene and protein expression when compared to non–TCR-primed CAR T cells. Single-cell RNA sequencing showed clonal expansion of anti-VSV CAR T cells and enhancement of effector-associated genes with VSV-mediated CAR T cell expansion. CD4 T cells played a pivotal role in the development of these TCR-primed CAR T cells. These results provide a strong rationale both for a novel use of systemic oncolytic virotherapy and for directly exploiting the CAR T cell TCR to fine tune the CAR T cell phenotype and function.

3 August 2025 in bioRxiv
Verified
Preprint
Open access
NENatalie M Elliott
Natalie M Elliott
BKBenjamin L Kendall
Benjamin L Kendall
SDSouyma Dutta
Souyma Dutta
DSDaipayan Sarkar
Daipayan Sarkar
JVJohn W Vant
John W Vant
MBMitesh Borad
Mitesh Borad
The clinical efficacy of systemic oncolytic virotherapy (OV) is constrained by the rapid development of neutralizing antibodies (nAbs), which prevent repeat systemic administration, a critical barrier to sustained anti-tumor immunity. Vesiculoviruses offer potent oncolytic and immunogenic potential. However, leveraging their serological diversity for repeat dosing remains unexplored. We generated a library of chimeric vesiculovirus vectors incorporating glycoproteins from less well characterized vesiculovirus species. We evaluated vector replication, infectivity, interferon (IFN) responses, and oncolysis in vitro, alongside assessments of neutralization resistance using patient sera, monoclonal antibodies, and in silico structural modeling. In vivo studies assessed tumor delivery, immune activation, and therapeutic efficacy following intravenous administration. The vesiculovirus library exhibited broad tumor infectivity, distinct IFN-stimulatory profiles, and variable oncolytic activity. Neutralization assays and computational modeling identified serological distinctness across vectors, driven by hypervariable glycoprotein epitopes, enabling evasion of cross-neutralizing antibodies. Tumor delivery and anti-tumor immunity were preserved despite humoral barriers. Incorporating tumor-associated antigens (TAAs) further amplified anti-tumor responses, even in the context of anti-viral memory. Sequential administration of distinct vesiculovirus vectors induced robust immune activation and improved survival in a B16-OVA-IFNAR-/- model. Our findings establish a glycoprotein-diverse vesiculovirus platform capable of overcoming humoral immunity, enabling repeat intravenous dosing and sustained engagement of the tumor microenvironment. This strategy advances the field of oncolytic virotherapy by addressing a major translational barrier and lays the groundwork for future clinical studies integrating multi-vector, multi-dose immunovirotherapy with immune checkpoint blockade.

25 August 2026 in Cancer Immunology Research
Verified
Journal Article
Closed access
ACAlex Chen
Alex Chen
JPJosè S. Pulido
Josè S. Pulido
JTJason Tonne
Jason Tonne
MMMuriel Metko
Muriel Metko
JTJill Thompson
Jill Thompson
RVRichard D. Vile
Richard D. Vile
T-cell immune tolerance is established in part through the activity of the autoimmune regulator (AIRE) transcription factor in medullary thymic epithelial cells (mTEC) of the thymus. AIRE induces expression of peripheral tissue–specific self-antigens for presentation to naïve T cells to promote activation/deletion of autoreactive T cells. This traditional role of AIRE in mTECs is to prevent autoimmunity. Herein, we demonstrate that tumors mimic the role of AIRE in mTECs to evade immune rejection. We found that AIRE induced a profile of “selfness” at the RNA and protein levels which, when presented on major histocompatibility complexes (MHC), shielded the tumor from inherently self-tolerized T cells. Moreover, we describe an in vivo immunotherapy in which engineered changes in AIRE expression in tumor cells altered their profile of selfness, exposing both AIRE-modified and parental unmodified tumor cells to T-cell attack. Therefore, by resetting the immunologic selfness of cancer cells, this AIRE-mediated immunotherapy (i) converted a highly tolerized T-cell compartment into a tumor-reactive T-cell population; (ii) conferred upon nonimmunogenic tumors de novo sensitivity to immune checkpoint blockade; (iii) removed the need to identify potentially immunogenic tumor-associated antigens as targets for generation of T-cell responses; and (iv) lead to potent T cell–mediated rejection of aggressive, immunologically cold, nonimmunogenic tumors. Patient RNA sequencing data showed that the expression of AIRE predicted response to immune therapies with a strong correlation between AIRE expression and markers of T-cell receptor signaling, suggesting that our studies have therapeutic translational value.